Approval · Notice of Compliance 37025 · 2026
INVOKAMET: Notice of Compliance 37025
Issued March 3, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37025
- Date
- March 3, 2026
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph reformatted to the Master Template. Update to the Product Monograph with new safety information. Removal of the 150mg/500mg strength from the product Monograph. Update to Patient Medication Information. Update to package insert
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INVOKAMET | Not yet assigned | — |
Medicinal ingredients
- METFORMIN HYDROCHLORIDE 500 MG per TAB
- CANAGLIFLOZIN 50 MG per TAB
- METFORMIN HYDROCHLORIDE 1,000 MG per TAB
- CANAGLIFLOZIN 150 MG per TAB